|
|
 |
Braden M. Bohrmann, Managing Member
Brady Bohrmann joined Avalon in 2007 as a Venture Partner. He has over 20 years of experience as a venture capitalist and operating executive in both biotech and information technology. He serves on the boards of directors of Avalon portfolio companies Afraxis, Carolus, Pictela, Twinstrata, Cloudant, Inc. and Cloudkick, and is a board observer for Simulmedia, Ad Summos, and Nabbr. Mr. Bohrmann is currently winding up his responsibilities as a general partner of Masthead, an early-stage venture capital firm that has invested approximately $200 million since he co-founded it in 1997.
During his time at Masthead, Mr. Bohrmann has been responsible for managing all aspects of the fund, ranging from fund raising and investor relations to internal operations to direct investments and oversight of portfolio investments. His investment activities have focused on digital media and information technology companies including Tremor Media, Intercasting, Corp., chumby industries, ExpoTV, Nexaweb Technologies and Liquid Machines. While at Masthead he had worked closely with Rich Levandov on eight venture investments and co-invested with Avalon on chumby industries and Intercasting, Corp.
Previously, Mr. Bohrmann served as President and COO of Watson Technologies, a venture-capital-backed, privately held telecommunications hardware company, and CFO of Alpha-Beta Technology, a publicly held biotechnology company.
At Watson Technologies, Mr. Bohrmann was hired by the venture investors to help restructure and turn around this underperforming investment. At the board of directors' direction, Mr. Bohrmann led a restructuring that included a reduction-in-force of 17 of the 18 original employees. He was responsible for rebuilding the development, engineering and marketing functions and recruiting a new CEO, to whom he reported before leaving to form Masthead. The new CEO, who was recruited by Mr. Bohrmann, changed the company's approach to customer development and product development. This resulted in the company receiving more financial backing and licensing its technology.
Mr. Bohrmann joined Alpha-Beta shortly after its inception and was instrumental in its growth from a venture backed start up with five employees to a publicly held, fully integrated drug discovery and development company. During his time at Alpha-Beta, he raised over $150 million in private and public funding. Widely recognized by his peers for his innovative financing solutions, he led a taxable revenue bond offering to support construction of a $40 million drug production facility and was an early user of the private-investment-in-public-equity ("PIPE") structure in biotechnology.
Mr. Bohrmann holds a B.S. in finance from Babson College. He started his career at the Bank of Boston, where he worked in the specialized lending group in Boston and the bank's merchant banking subsidiary in London.
|
|
